BridgeBio Pharma reported a second-quarter loss of $0.78 per share, wider than the Zacks Consensus Estimate of a loss of $0.64 per share, while revenue of $243.68 million topped the consensus estimate by 9.46%. The loss compares with a loss of $0.95 per share a year earlier, and the revenue figure is up from $110.57 million in the prior-year quarter. The company has missed consensus EPS estimates in each of the last four quarters but has beaten revenue estimates in all four. Shares of BridgeBio Pharma have gained about 10.5% year to date, trailing the S&P 500's 13.3% advance.
BridgeBio Pharma IncQ2 loss wider than expected but revenue beat; mixed results.
Assembly Biosciences Inc